Immunocore charts the path for bispecifics in solid tumors with Phase III readout

With a positive Phase III readout in metastatic uveal melanoma, Immunocore has become the first company to solve one of the biggest challenges in immuno-oncology: applying T cell-engaging bispecifics to solid tumors. 

The data suggest an alternative bispecific structure, which uses a soluble TCR rather than an antibody to target cancer cells, is one path through the clinic for solid tumors...